ASTRAZENECA DL-,25 SP.ADR
ASTRAZENECA DL-,25 SP.ADR/ US0463531089 /
ZEGA
|
22/05/2024 8:08:23
|
Diferencia
+2.00
|
Volumen |
Bid12:26:32 |
Ask12:26:32 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
|
72.50EUR
|
+2.84%
|
0
Volumen de negocios: 0.00 |
72.00Volumen de oferta: 140 |
72.50Tamaño/ Volumen/ Formato de Ask: 140 |
224.18 mil millonesEUR |
- |
- |
Descripción de negocio
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Consejo de gestión & Consejo de supervisión
| CEO |
| Pascal Soriot |
| Consejo de gestión |
| Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Menelas (Mene) Pangalos, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
| Consejo de supervisión |
| Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg |
Datos de la empresa
| Nombre: |
AstraZeneca plc |
| Dirección: |
1 Francis Crick Avenue Cambridge Biomedical Campus,Cambridge, CB2 0AA United Kingdom |
| Teléfono: |
0800 783 0033 |
| Fax: |
+44-20-7604-8151 |
| E-mail: |
Medical.InformationU...eca.com
Medical.InformationUK@astrazeneca.com
|
| Internet: |
www.astrazeneca.com |
| Industria: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Subsector: |
Pharmaceuticals |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
- |
| Fecha de OPI: |
06/04/1999 |
Calendario de la empresa
|
CW 30 | 25/07/2024
Interim Report 2nd Quarter/6 Months
|
|
CW 32 | 08/08/2024
Ex-Dividend
|
|
CW 32 | 09/08/2024
Record Date
|
|
CW 37 | 09/09/2024
Dividend Payment
|
|
CW 46 | 12/11/2024
Interim Report 3rd Quarter/9 Months
|
